Healthy volunteers help uncover drug interactions for lung disease therapy
NCT ID NCT07588646
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This study looked at how a new medicine called HEC585 interacts with two existing drugs (pirfenidone and nintedanib) used for idiopathic pulmonary fibrosis (IPF), a serious lung disease. Thirty-three healthy adults took part to measure drug levels and check for side effects. The goal was to gather safety and interaction data, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Xuhui Central Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.